» Articles » PMID: 22140056

Repeated Transplantation of Hepatocytes Prevents Fulminant Hepatitis in a Rat Model of Wilson's Disease

Overview
Journal Liver Transpl
Date 2011 Dec 6
PMID 22140056
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The outcome of consecutive hepatocyte transplants was explored in a rat model of Wilson's disease before the onset of fulminant hepatitis without preconditioning regimens. Rats received a high-copper diet in order to induce a rapid induction of liver failure. Sham-operated rats (15/15) developed jaundice and fulminant hepatitis, and they died within 4 weeks of first transplantation. Despite the continuation of a high dietary copper challenge, long-term survival was observed for a notable proportion of the transplanted animals (7/18). All survivors displayed normalized levels of hepatitis-associated serum markers and ceruloplasmin oxidase activity by posttransplant days 50 and 98, respectively. The liver copper concentrations, the liver histology, and the expression of marker genes were significantly restored within 4 months of transplantation in comparison with the control group. The high expression of a copper transporter gene (ATPase Cu++ transporting beta polypeptide) in the livers of the survivors indicated a high rate of repopulation by donor hepatocytes. Our data suggest that repeated cell transplantation can overcome the limitations of a single therapy session in rats with severe hepatic disease by functionally restoring the host liver without preconditioning.

Citing Articles

Hepatic progenitor cells reprogrammed from mouse fibroblasts repopulate hepatocytes in Wilson's disease mice.

Liu K, Li L, He Y, Zhang S, You H, Wang P Stem Cell Res Ther. 2025; 16(1):131.

PMID: 40069754 PMC: 11899129. DOI: 10.1186/s13287-025-04253-1.


Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson's Disease.

Choi W, Cha S, Kim K Cells. 2024; 13(14.

PMID: 39056796 PMC: 11274827. DOI: 10.3390/cells13141214.


Research progress in stem cell therapy for Wilson disease.

Xiong X, Gao C, Meng X, Liu A, Gong X, Sun Y Regen Ther. 2024; 27:73-82.

PMID: 38525238 PMC: 10959646. DOI: 10.1016/j.reth.2024.03.005.


Neurological-Type Wilson Disease: Epidemiology, Clinical Manifestations, Diagnosis, and Management.

Kipker N, Alessi K, Bojkovic M, Padda I, Parmar M Cureus. 2023; 15(4):e38170.

PMID: 37252588 PMC: 10224700. DOI: 10.7759/cureus.38170.


CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson's disease.

Wei R, Yang J, Cheng C, Ho W, Li N, Hu Y JHEP Rep. 2021; 4(1):100389.

PMID: 34877514 PMC: 8633686. DOI: 10.1016/j.jhepr.2021.100389.